BCAX (Bicara Therapeutics) Interest Expense : $0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Bicara Therapeutics's interest expense for the three months ended in Sep. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Bicara Therapeutics's Operating Income for the three months ended in Sep. 2024 was $ -20.63 Mil. Bicara Therapeutics's Interest Expense for the three months ended in Sep. 2024 was $ 0.00 Mil. GuruFocus does not calculate Bicara Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bicara Therapeutics Interest Expense Historical Data

The historical data trend for Bicara Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics Interest Expense Chart

Bicara Therapeutics Annual Data

Trend

Dec22

Dec23

Interest Expense

-0.11

Bicara Therapeutics Quarterly Data
	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial			-	-	-	-	-

Bicara Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Bicara Therapeutics (NAS:BCAX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Bicara Therapeutics's Interest Expense for the three months ended in Sep. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was $-20.63 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was $0.14 Mil.

Bicara Therapeutics's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

GuruFocus does not calculate Bicara Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Bicara Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Bicara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116

Website

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.